12Jul/13

BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive … – The Oncology Report

BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive
The Oncology Report
CHICAGO – The mTOR inhibitor everolimus appears to be effective at overcoming trastuzumab resistance in patients with advanced HER2-positive breast cancer, based on findings from the BOLERO-3 trial. The 572 patients studied all had locally advanced 

and more »